SCHEMBL4144872

SCHEMBL4144872

NC1(Br)CCCc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 6/20 0.56
MAOB P27338 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
AKR1B1 P15121 2/20 0.44
TSHR P16473 2/20 0.41
SIGMAR1 Q99720 3/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
DRD2 P14416 1/20 0.41
NFKB1 P19838 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTR2B P41595 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30112838 0.79 KDM1A (0.59) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL1101137 0.79 KDM1A (0.59) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL6440070 0.76 KDM1A (0.56) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL9396129 0.76 KDM1A (0.56) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL3539945 0.76 KDM1A (0.56) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL6917152 0.76 KDM1A (0.47) KDM1AMEN1KMT2AAKR1B1TSHR
SCHEMBL5369769 0.76 KDM1A (0.56) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL643388 0.76 KDM1A (0.66) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL1273553 0.76 KDM1A (0.66) KDM1AMAOBMEN1KMT2AAKR1B1
SCHEMBL11696762 0.74 KDM1A (0.54) KDM1AMEN1KMT2AAKR1B1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111757875-B Dihydrobenzofuran and indene analogs as myocardial segment inhibitors 赛特凯恩蒂克公司 2024-01-09 CN disclosed
CN-106572658-B Molecule and relative intermediate, composition and method with certain disinsection efficiencies 美国陶氏益农公司 2019-11-08 CN disclosed
CN-106748809-B A method of adjacent halogen arylamine is prepared based on C-H activation arylamine class 浙江工业大学 2019-05-31 CN disclosed
CN-106748809-A A kind of method that adjacent halogen arylamine is prepared based on C H activation arylamine classes 浙江工业大学 2017-05-31 CN disclosed
CN-106572658-A Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto 美国陶氏益农公司 2017-04-19 CN disclosed
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US disclosed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP disclosed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 KDM1A 4096/4885MAOB 477/4885MEN1 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.